Chi­nese an­ti­body mak­er, famed for Ebo­la cock­tail, notch­es $160M as it fo­cus­es on can­cer, au­toim­mune drugs

Big name in­vestors have come to­geth­er to bring Chi­nese biotech Mab­works’ Se­ries C haul to $160 mil­lion, boost­ing a bi­o­log­ics pipeline that spans a num­ber of can­cers and au­toim­mune dis­eases.

Mab­works made an ap­pear­ance on the in­ter­na­tion­al stage back in 2015 for its role in man­u­fac­tur­ing an Ebo­la an­ti­body that was used to treat two pa­tients. That drug, MIL77, re­mains one of three drugs tout­ed on the front page of the com­pa­ny’s web­site; the oth­er two are an­ti­bod­ies that tar­get HER2 and CD20, re­spec­tive­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.